Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. Ivagnès A, et al. Among authors: routy b. Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018. Oncoimmunology. 2017. PMID: 30524877 Free PMC article.
Prime time for immune-checkpoint targeted therapy at ASCO 2015.
Marabelle A, Routy B, Michels J, Kroemer G, Zitvogel L. Marabelle A, et al. Among authors: routy b. Oncoimmunology. 2015 Aug 12;5(3):e1068494. doi: 10.1080/2162402X.2015.1068494. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141332 Free PMC article. Review.
COVID-19: a challenge for oncology services.
Routy B, Derosa L, Zitvogel L, Kroemer G. Routy B, et al. Oncoimmunology. 2020 May 5;9(1):1760686. doi: 10.1080/2162402X.2020.1760686. Oncoimmunology. 2020. PMID: 32923119 Free PMC article. No abstract available.
Immunological off-target effects of imatinib.
Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Zitvogel L, et al. Among authors: routy b. Nat Rev Clin Oncol. 2016 Jul;13(7):431-46. doi: 10.1038/nrclinonc.2016.41. Epub 2016 Mar 31. Nat Rev Clin Oncol. 2016. PMID: 27030078 Review.
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.
Daillère R, Routy B, Goubet AG, Cogdill A, Ferrere G, Alves-Costa Silva C, Fluckiger A, Ly P, Haddad Y, Pizzato E, Thelemaque C, Fidelle M, Mazzenga M, Roberti MP, Melenotte C, Liu P, Terrisse S, Kepp O, Kroemer G, Zitvogel L, Derosa L. Daillère R, et al. Among authors: routy b. Oncoimmunology. 2020 Jul 20;9(1):1794423. doi: 10.1080/2162402X.2020.1794423. Oncoimmunology. 2020. PMID: 32934888 Free PMC article. Review.
Microbiome and Anticancer Immunosurveillance.
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Zitvogel L, et al. Among authors: routy b. Cell. 2016 Apr 7;165(2):276-87. doi: 10.1016/j.cell.2016.03.001. Cell. 2016. PMID: 27058662 Free article. Review.
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L. Messaoudene M, et al. Among authors: routy b. Ann Oncol. 2019 Jun 1;30(6):934-944. doi: 10.1093/annonc/mdz112. Ann Oncol. 2019. PMID: 30924846 Free PMC article.
Anticancer effects of the microbiome and its products.
Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Zitvogel L, et al. Among authors: routy b. Nat Rev Microbiol. 2017 Aug;15(8):465-478. doi: 10.1038/nrmicro.2017.44. Epub 2017 May 22. Nat Rev Microbiol. 2017. PMID: 28529325 Review.
115 results